Apellis Pharmaceuticals (NASDAQ: MNLO) and Menlo Therapeutics (NASDAQ:MNLO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
Insider & Institutional Ownership
51.7% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 62.1% of Menlo Therapeutics shares are held by institutional investors. 9.3% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of current recommendations for Apellis Pharmaceuticals and Menlo Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Apellis Pharmaceuticals presently has a consensus price target of $35.60, suggesting a potential upside of 83.88%. Menlo Therapeutics has a consensus price target of $34.60, suggesting a potential upside of 350.52%. Given Menlo Therapeutics’ higher possible upside, analysts clearly believe Menlo Therapeutics is more favorable than Apellis Pharmaceuticals.
Valuation & Earnings
This table compares Apellis Pharmaceuticals and Menlo Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Apellis Pharmaceuticals||N/A||N/A||-$51.00 million||($3.67)||-5.28|
|Menlo Therapeutics||$4.58 million||38.53||-$29.07 million||($5.69)||-1.35|
Menlo Therapeutics has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Menlo Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Apellis Pharmaceuticals and Menlo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Menlo Therapeutics beats Apellis Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. The company develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin. It also develops APL-9 for intravenous administration in systemic indications, which is in single ascending dose Phase I clinical trial. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.
Menlo Therapeutics Company Profile
Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It is also developing products that are in Phase II clinical trials to treat pruritus associated with psoriasis, atopic dermatitis, and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.